Herombopag + rhTPO in Severe Immune Thrombocytopenia
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Severe immune thrombocytopenia (ITP) is a life-threatening acquired hemorrhagic disease with
dramatically decreased platelet number and clinical bleeding symptoms. Some patients with
severe ITP did not respond to first-line treatment including steroids and IVIG. It was
critical for them to use effective treatments to promote platelet and reduce the risk of
fatal bleeding. In this study, severe ITP will be treated hetrombopag, rhTPO, and the
combination of hetrombopag and rhTPO, respectively. The effect evaluation includes the
increase of platelet number, decrease of bleeding scores. Changes of coagulation, platelet
activation, fribrinolysis influence, and thrombotic events will also be accessed for safety
of the treatments. The aim of this study is to demonstrate that the combination therapy for
severe ITP is more effective than the other two monotherapy and does not increase thrombotic
events or thrombosis risk.